Evaluation of ivabradine in left ventricular dyssynchrony and reverse remodeling in patients with chronic heart failure.
dyssynchrony
heart failure
ivabradine
Journal
Journal of arrhythmia
ISSN: 1880-4276
Titre abrégé: J Arrhythm
Pays: Japan
ID NLM: 101263026
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
04
03
2020
revised:
13
06
2020
accepted:
18
06
2020
entrez:
13
8
2020
pubmed:
13
8
2020
medline:
13
8
2020
Statut:
epublish
Résumé
Ivabradine is a pharmacological agent used in patients with heart failure and sinus rhythm. Its only known pharmacological effect is to slow the heart rate. In this study, we investigated the impact of ivabradine on dyssynchrony parameters in heart failure patients. In this study, we assigned 55 patients taking medication for heart failure to receive ivabradine in addition (Group I). Twenty healthy volunteers comprised Group II. Echocardiographic measurements (dyssynchrony, left ventricular volumes and left ventricular ejection fraction) were taken at baseline, 1 month, and 3 months. A total of 32 heart failure patients in Group I completed the study. There was significant improvement in dyssynchrony parameters after ivabradine treatment in Group I. Interventricular dyssynchrony (IVD) decreased from 42.0 ± 24.4 milliseconds at baseline to 33.6 ± 20.7 milliseconds at 1 month ( The addition of ivabradine to heart failure treatment improves cardiac dyssynchrony parameters in chronic systolic heart failure patients with sinus rhythm.
Identifiants
pubmed: 32782651
doi: 10.1002/joa3.12398
pii: JOA312398
pmc: PMC7411195
doi:
Types de publication
Journal Article
Langues
eng
Pagination
762-767Informations de copyright
© 2020 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of Japanese Heart Rhythm Society.
Déclaration de conflit d'intérêts
None declared.
Références
J Am Coll Cardiol. 2000 Apr;35(5):1221-7
pubmed: 10758964
Am J Cardiol. 2005 Jul 15;96(2):267-9
pubmed: 16018855
Heart Vessels. 2014 Jan;29(1):88-96
pubmed: 23519525
J Am Coll Cardiol. 2004 Nov 2;44(9):1834-40
pubmed: 15519016
J Am Coll Cardiol. 2002 Nov 6;40(9):1615-22
pubmed: 12427414
N Engl J Med. 2004 May 20;350(21):2140-50
pubmed: 15152059
Circulation. 2003 Apr 22;107(15):1985-90
pubmed: 12668512
Int J Cardiol. 2011 Sep 1;151(2):218-24
pubmed: 21764469
J Am Coll Cardiol. 2004 Jan 21;43(2):248-56
pubmed: 14736445
Eur Heart J. 2012 Jul;33(14):1787-847
pubmed: 22611136
Circulation. 2004 Apr 6;109(13):1674-9
pubmed: 14981003
Ann Noninvasive Electrocardiol. 2005 Oct;10(4 Suppl):34-43
pubmed: 16274414
Pharmacol Res. 2006 May;53(5):399-406
pubmed: 16638640
Cardiol J. 2014;21(4):434-41
pubmed: 24142686
Trends Cardiovasc Med. 2019 Aug;29(6):335-342
pubmed: 30401603
Acta Cardiol Sin. 2017 Jan;33(1):58-65
pubmed: 28115808
Am J Physiol Heart Circ Physiol. 2011 Jan;300(1):H366-73
pubmed: 20952661
Hypertension. 2012 May;59(5):949-57
pubmed: 22493071
Lancet. 2010 Sep 11;376(9744):875-85
pubmed: 20801500
J Card Fail. 2005 Sep;11(7):523-8
pubmed: 16198248
Am J Cardiol. 2004 Jun 15;93(12):1504-9
pubmed: 15194021
Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H590-8
pubmed: 17384136
J Am Coll Cardiol. 2007 Feb 20;49(7):778-83
pubmed: 17306707
Am Heart J. 2002 Jun;143(6):1085-91
pubmed: 12075267
N Engl J Med. 2005 Apr 14;352(15):1539-49
pubmed: 15753115
Am J Physiol Heart Circ Physiol. 2009 Feb;296(2):H435-41
pubmed: 19074674
Eur Heart J. 2011 Oct;32(20):2507-15
pubmed: 21875858